Table 3.
Baseline patient and lesion characteristicsa
| Patient characteristics | Percentage reportedb (%) | |
|---|---|---|
| Patients, (n) | 310 | 100 |
| Ankles, (n) | 323 | 100 |
| Sex, males/females, (%) | 65/35 | 100 |
| Age, years (range) | 37.0 (24.7–39.2) | 100 |
| Body mass index, kg/m2 (range) | 24.7 (24.3–26.4) | 69 |
| History of trauma, (%) | 86 | |
| Yes | 60 | |
| No | 40 | |
| Duration of symptoms, months (range) | 10.2 (17.0–28.1) | 84 |
| Follow-up, years (range) | 13.0 (9.5–13.9) | 100 |
| Method of BMS, n (%) | 100 | |
| Debridement and microfracturing or drilling | 312 (97%) | |
| Debridement alone | 11 (3%) | |
| Lesion characteristics, n (%) | ||
| Primary, (%) | 96 | 94 |
| Non-primary, (%) | 4 | 94 |
| Presence of cyst, n (%) | 24 | 63 |
| Lesion size | ||
| Area, mm2 (range) | 100.1 (74.2–105.3) | 78 |
| > 150 mm2 | 21% | 63 |
| < 150 mm2 | 79% | |
| Depth, mm (range) | 7.1 (NA) | 15 |
| Lesion location, n (%) | ||
| Medial | 229 (71%) | 99 |
| Central | 10 (3%) | 99 |
| Lateral | 83 (26%) | 99 |
n number, BMS bone marrow stimulation, mm millimetre
aData are presented as weighted means (range of means) and percentages
bPercentage frequency of reporting by number of ankles